discoveri
gene
express
control
watsoncrick
basepair
small
rna
messeng
rna
contain
complementari
sequenc
process
known
rna
interfer
markedli
advanc
understand
eukaryot
gene
regul
function
abil
short
rna
sequenc
modul
gene
express
provid
power
tool
studi
gene
function
set
revolution
treatment
diseas
remark
despit
one
decad
discoveri
phenomenon
alreadi
use
therapeut
human
clinic
trial
biotechnolog
compani
focu
rnainterferencebas
therapeut
alreadi
publicli
trade
rna
gener
consid
passiv
intermedi
carri
inform
dna
protein
synthesi
discoveri
catalyt
rna
earli
merit
share
nobel
prize
tom
cech
sidney
altman
concept
rna
world
idiom
creat
walter
gilbert
propos
today
common
express
rna
claim
pivot
place
cellular
biolog
ten
year
ago
rna
function
repertoir
expand
discoveri
nematod
caenorhabd
elegan
doublestrand
rna
dsrna
trigger
silenc
complementari
messeng
rna
sequenc
term
rna
interfer
rnai
born
shortli
thereaft
short
dsrna
short
interf
rna
sirna
review
ref
gener
artifici
use
demonstr
process
also
occur
mammalian
cell
usual
alway
without
trigger
innat
immun
sy
tem
normal
recogn
rna
part
antivir
defenc
mechan
see
page
knowledg
small
rna
affect
gene
express
tremend
impact
basic
appli
research
rnai
current
one
promis
new
approach
diseas
therapi
rnai
could
trigger
vivo
mammal
first
shown
anim
infect
hepat
b
viru
follow
first
therapeut
applic
sirna
sirna
target
fa
mrna
mous
model
autoimmun
hepat
result
protect
treat
anim
liver
fibrosi
six
year
discoveri
rnai
first
sirnabas
human
therapeut
develop
treatment
wet
agerel
macular
degener
enter
phase
clinic
trial
rnai
one
fastest
advanc
field
biolog
flow
discoveri
give
true
mean
express
bench
bedsid
although
much
known
mechan
rnai
number
challeng
applic
genesilenc
technolog
need
overcom
one
rnai
fundament
import
regulatori
mechan
cell
tap
interest
therapeut
benefit
could
result
side
effect
exogen
introduc
dsrna
sequenc
sequest
compon
make
cellular
machineri
involv
gene
silenc
see
page
therebi
reduc
access
machineri
class
small
rna
known
microrna
mirna
enter
natur
cellular
pathway
addit
synthet
sirna
contain
sequenc
motif
induc
type
interferon
respons
stimul
product
proinflammatori
cytokin
past
year
mani
scientist
search
solut
overcom
limit
increas
safeti
potenti
rnaibas
therapeut
articl
explor
recent
strategi
minim
undesir
secondari
effect
describ
new
approach
deliveri
discuss
rnai
therapi
test
anticip
technolog
appli
increas
rang
diseas
potenti
problem
solut
could
one
day
transform
rnai
convent
treatment
human
diseas
warrant
care
attent
effector
rna
molecul
rnai
consist
nucleotid
complex
protein
compon
rnainduc
silenc
complex
risc
catalyt
core
plant
anim
except
singlecel
organ
member
highli
conserv
argonaut
protein
famili
small
rna
silenc
gene
express
two
mechan
posttranscript
gene
silenc
ptg
transcript
gene
silenc
tg
fig
ptg
turn
divid
two
main
mechan
direct
sequencespecif
cleavag
translat
repress
rna
degrad
direct
sequencespecif
cleavag
occur
target
mrna
perfectli
complementari
sirna
degrad
sitespecif
cleavag
risc
translat
repress
rna
degrad
occur
small
rna
guid
sequenc
limit
complementar
target
seed
region
nucleotid
end
guid
strand
basepair
usual
occur
untransl
region
utr
latter
mechan
use
mirna
tg
demonstr
schizosaccharomyc
pomb
fission
yeast
plant
recent
mammalian
cell
pomb
process
mediat
rnainduc
transcript
silenc
complex
rit
contain
chromodomain
protein
glycin
tryptophan
gw
repeatcontain
protein
ref
see
page
although
mammalian
cell
mechan
smallrnadirect
silenc
occur
still
hotli
debat
shown
integr
overal
process
recent
mirna
shown
regul
transcript
subunit
rna
polymeras
iii
pol
iii
human
cell
cultur
endogen
small
rna
found
variou
organ
includ
human
mice
fruitfli
drosophila
melanogast
c
elegan
mani
origin
transposon
virus
repetit
sequenc
character
interact
piwi
subfamili
piwi
clade
argonaut
protein
thu
name
piwiinteract
rna
pirna
identif
pirna
restrict
germlin
cell
recent
new
class
endogen
sirna
endosirna
esirna
identifi
gonad
somat
tissu
melanogast
mous
oocyt
mice
endosirna
propos
regul
retrotransposon
movement
sever
famili
small
rna
includ
repeatassoci
sirna
rasirna
tini
noncod
rna
tncrna
transact
sirna
tasirna
scan
rna
scnrna
tabl
found
fungi
plant
anim
far
none
observ
mammal
evid
suggest
pirna
act
differ
cellular
pathway
sirna
mirna
could
offer
altern
target
strategi
therapeut
target
cellular
gene
target
exogen
introduct
sirna
take
advantag
endogen
ptg
mechan
sirna
either
transfect
cell
enter
risc
directli
gener
within
cell
gene
express
use
vector
contain
pol
ii
pol
iii
promot
rnai
trigger
express
anim
plant
pomb
form
mirna
short
hairpin
rna
shrna
cleav
small
rna
enzym
drosha
andor
dicer
case
two
strand
rna
trigger
complet
complementari
passeng
strand
cleav
ref
leav
behind
singlestrand
guid
sequenc
act
templat
recognit
target
gene
sequenc
risc
fig
impend
therapeut
applic
base
rnai
propos
use
direct
introduct
synthet
sirna
advantag
use
chemic
synthes
molecul
chemic
modif
introduc
increas
stabil
promot
efficaci
block
bind
unintend
target
contain
sequenc
mismatch
specif
offtarget
effect
reduc
abrog
potenti
immunostimulatori
effect
gener
offtarget
effect
howev
effect
molecul
transient
wherea
promoterexpress
shrna
mirna
potenti
mediat
longterm
silenc
singl
applic
convent
sirna
nucleotid
dinucleotid
overhang
mimic
dicer
cleavag
product
sirna
achiev
equival
level
target
knockdown
largescal
sirna
screen
often
perform
given
target
find
potent
inhibitor
yield
rule
sirna
design
exampl
facilit
incorpor
risc
end
antisens
guid
strand
design
lower
thermodynam
stabil
end
sens
strand
proport
nucleotid
guanosin
cytidin
around
lower
target
known
proteinbind
site
mrna
regulatori
region
avoid
bind
regulatori
protein
may
block
sirnatarget
pair
reason
intramolecular
structur
target
avoid
statist
analys
also
found
prefer
certain
nucleotid
specif
posit
within
sirna
mani
comput
program
avail
identifi
optim
target
sequenc
given
gene
one
artifici
neural
network
use
develop
genomewid
sirna
librari
human
identifi
effect
sirna
target
chemic
modif
often
includ
design
synthet
sirna
select
addit
phosphorothio
linkag
substitut
fluoropyrimidin
ribos
certain
posit
compromis
sirna
activ
concomitantli
increas
resist
ribonucleas
import
vivo
applic
singl
group
passeng
strand
sirna
duplex
abrog
activ
tolllik
receptor
prevent
tox
iciti
due
activ
type
interferon
pathway
gene
express
recent
demonstr
acid
arabinonucl
acid
modif
increas
serum
stabil
potenc
sirna
chemic
modif
also
import
advantag
decreas
block
activ
sirna
sens
passeng
strand
therebi
reduc
specif
offtarget
effect
modif
addit
lauric
acid
lithochol
acid
cholesterol
deriv
made
increas
cellular
uptak
current
one
main
hurdl
rnai
therapi
therapeut
applic
sirna
requir
effect
deliveri
target
cell
tissu
two
main
strategi
deliveri
chemic
synthes
sirna
nonvir
deliveri
deliveri
shrnaencod
gene
engin
virus
ultim
gener
sirna
transcript
target
cell
size
neg
charg
sirna
easili
cross
cell
membran
deliveri
therefor
one
major
challeng
rnai
technolog
variou
mean
deliveri
develop
test
murin
nonhuman
primat
model
rang
inject
nake
rna
target
organ
lung
eye
system
deliveri
rna
nanoparticl
complex
polyc
attach
cholesterol
group
conjug
cellsurfac
receptor
deliveri
approach
detail
fig
two
polym
examin
deliveri
properti
atelocollagen
chitosan
chitosan
mucoadhes
properti
use
intranas
deliveri
bronchiolar
epitheli
cell
intranas
deliveri
prove
effect
mean
deliv
sirna
mice
nonhuman
primat
block
respiratori
syncyti
viru
infect
upper
respiratori
tract
fact
deliveri
sirna
mucos
membran
seem
effect
approach
gener
exampl
intravagin
deliveri
lipidencapsul
sirna
target
herp
simplex
viru
provid
protect
lethal
viral
infect
twothird
sirnatr
mice
target
antiapolipoprotein
b
apob
peroxisom
proliferatoractiv
sirna
liver
achiev
mean
membraneact
polym
mask
activ
reach
endosom
result
deliveri
sirna
hepatocyt
simpl
intraven
inject
differ
sirna
deliveri
approach
use
transferrin
conjug
cyclodextrinpolyc
polym
deliv
sirna
target
ewe
sarcoma
fusion
mrna
mean
transferrin
receptor
mice
result
inhibit
tumour
progress
conjug
sirna
cholesterol
group
permit
deliveri
liver
jejunum
downregul
target
apob
lead
consequ
lower
blood
cholesterol
level
murin
model
system
import
advanc
sirna
deliveri
success
applic
stabl
nucleicacid
lipid
particl
decor
poli
ethylen
glycol
peg
polym
chain
term
snalp
deliveri
sirna
direct
apob
mrna
apobtarget
sirna
liver
nonhuman
primat
case
sirna
effect
singl
intraven
inject
last
day
result
greater
target
knockdown
toxic
excit
result
increas
confid
potenti
therapeut
sirna
treat
liver
diseas
recent
approach
vivo
deliveri
target
particular
organ
primarili
eye
lung
liver
signific
advanc
target
sirna
specif
class
leukocyt
involv
gut
inflamm
report
studi
cyclin
target
sirna
load
stabil
nanoparticl
surfac
incorpor
antibodi
specif
receptor
express
leukocyt
target
sirnacontain
nanoparticl
downregul
cyclin
target
suppress
leukocyt
prolifer
revers
experiment
induc
coliti
mice
deliveri
sirna
nervou
system
particularli
challeng
brain
notori
refractori
target
difficulti
cross
bloodbrain
barrier
howev
deliveri
sirna
peripher
nervou
system
direct
infus
brain
relief
chronic
pain
anxieti
demonstr
rat
conjug
liposom
antibodi
neuropeptid
also
use
deliv
sirna
murin
brain
nevertheless
method
target
neuron
less
invas
altern
direct
cranial
inject
requir
make
therapi
palat
recent
studi
unlock
possibl
select
deliveri
sirna
central
nervou
system
system
intraven
inject
sirna
involv
design
target
japanes
enceph
viru
conjug
short
peptid
deriv
rabi
viru
glycoprotein
bind
neuron
cell
acetylcholin
receptor
transvascular
deliveri
mice
treat
therapeut
sirna
surviv
infect
japanes
enceph
viru
wherea
untreat
control
die
complic
infect
anoth
interest
approach
allow
system
target
sirna
deliveri
use
protamineantibodi
fusion
protein
protamin
moieti
link
heavychain
antigenbind
region
fab
antibodi
human
immunodefici
viru
envelop
protein
posit
charg
protamin
bind
neg
charg
sirna
target
hiv
gene
gag
allow
select
deliveri
cell
express
envelop
protein
surfac
result
intern
antibodysirna
complex
releas
sirna
downregul
hiv
gagencod
transcript
murin
model
vivo
studi
fusion
protamin
antibodi
specif
hormon
receptor
allow
sirna
target
cancer
cell
express
receptor
similar
technolog
specif
target
deliveri
base
aptamerrnai
chimaera
aptam
vitroevolv
synthet
prepar
nucleic
acid
select
bind
specif
ligand
rna
aptam
design
bind
prostatespecif
membran
antigen
psma
also
known
link
sirna
bind
aptam
psma
receptor
result
select
deliveri
prostat
cancer
cell
sirna
target
prosurviv
gene
intratumor
inject
sirna
sirna
conjug
mous
xenograft
model
result
trigger
apoptosi
growth
inhibit
tumour
regress
differ
conjug
sirna
vitaminacoupl
liposom
succeed
deliv
antifibrot
sirna
hepat
stellat
cell
produc
respons
liver
damag
studi
multipl
sirna
treatment
target
collagen
chaperoneencod
gene
revers
liver
fibrosi
prevent
collagen
deposit
increas
surviv
rat
provid
potenti
therapeut
approach
treat
liver
cirrhosi
also
noteworthi
recent
report
librari
lipidlik
molecul
lipidoid
select
sirna
deliveri
variou
tissu
altern
mean
trigger
rnai
promoterexpress
sirna
sequenc
process
shrna
mirna
mimic
gene
encod
hairpin
structur
commonli
insert
backbon
viral
vector
control
pol
ii
pol
iii
promot
potenti
advantag
vector
deliveri
singl
administr
trigger
longterm
express
therapeut
rnai
particularli
appropri
chronic
viral
diseas
hiv
viral
hepat
lentivir
vector
use
success
deliv
shrna
construct
variou
mammalian
system
exampl
shown
downregul
activ
ra
oncogen
lentiviraldeliv
shrna
result
suppress
tumour
growth
mice
downregul
express
mutant
form
superoxid
dismutas
mous
model
amyotroph
later
sclerosi
delay
onset
diseas
recent
lentivir
vector
use
deliv
shrna
regener
satellit
cell
repair
old
tissu
age
injur
muscl
viralvector
express
shrna
also
explor
mous
model
neurodegen
disord
huntington
diseas
alzheim
diseas
deliv
gene
central
nervou
system
adenovir
vector
prove
use
instanc
direct
brain
inject
adenovir
vector
express
shrna
direct
mrna
encod
polyqharbour
transcript
spinocerebellar
ataxia
type
shown
effect
treatment
mous
model
disord
despit
success
viral
deliveri
import
bear
mind
although
virus
nonpathogen
still
potenti
immunogen
anoth
major
concern
techniqu
risk
incur
mutat
viral
sequenc
caus
insert
mutagenesi
trigger
aberr
gene
express
howev
viral
vector
transduc
divid
nondivid
cell
yield
prolong
express
therapeut
gene
need
deliv
larg
dose
ultim
therapeut
gene
express
larg
quantiti
potenti
caus
toxic
immunogen
critic
paramet
toler
longterm
express
efficaci
abil
regul
express
target
taken
consider
choos
deliveri
method
ideal
deliveri
system
everi
applic
rather
deliveri
method
need
tailor
applic
new
technolog
sirna
move
clinic
unpreced
pace
exampl
diseas
sirnatarget
strategi
current
investig
describ
first
sirna
protocol
grant
investig
new
drug
ind
statu
test
human
clinic
trial
vascular
endotheli
growth
factor
vegf
target
sirna
bevasiranib
acuiti
pharmaceut
philadelphia
pennsylvania
treatment
wet
agerel
macular
degener
see
tabl
summari
ongo
sirna
clinic
trial
involv
overgrowth
blood
vessel
behind
retina
caus
sever
irrevers
loss
vision
affect
million
peopl
unit
state
alon
predict
million
individu
worldwid
diseas
preclin
studi
bevasiranib
mice
show
reduc
neovascular
result
downregul
vegf
express
direct
ocular
inject
sirna
sirna
phase
iii
trial
also
phase
ii
clinic
trial
treatment
diabet
macular
oedema
conclus
trial
sever
hundr
patient
receiv
sirna
treatment
two
compani
also
focus
sirnabas
treatment
macular
degener
merck
sirna
therapeut
san
francisco
california
sirna
target
vegf
receptor
quark
pharmaceut
fremont
california
collabor
silenc
therapeut
london
berlin
previous
sr
pharma
one
target
hypoxiainduc
gene
also
known
known
involv
diseas
progress
sirna
licens
pfizer
uk
run
phase
iiia
clinic
trial
quark
pharmaceut
also
receiv
ind
statu
anoth
preclin
trial
current
enrol
patient
trial
sirna
target
mrna
encod
protein
inhibit
delay
induct
celldeath
pathway
therebi
reduc
acut
kidney
injuri
surgeri
calando
pharmaceut
pasadena
california
meanwhil
initi
phase
clinic
trial
solid
tumour
use
sirna
target
subunit
ribonucleotid
reductas
enzym
requir
synthesi
dna
build
block
importantli
trial
first
util
receptormedi
deliveri
sirna
encapsul
cyclodextrin
particl
decor
transferrin
result
uptak
cell
express
transferrin
receptor
highli
express
cancer
cell
surfac
clinic
trial
perform
acuiti
pharmaceut
merck
sirna
therapeut
success
stabil
patient
condit
degener
improv
vision
without
advers
effect
result
engend
great
optim
intravitr
inject
sirna
stun
turn
event
report
kleinman
et
al
demonstr
observ
decreas
vascular
could
consequ
sirnaspecif
effect
angiogenesi
rather
nonspecif
activ
tolllik
receptor
subsequ
activ
interleukin
turn
downregul
vegf
word
target
control
sirna
mediat
nonspecif
inhibit
angiogenesi
direct
interact
sirna
cellular
uptak
necessari
effect
involv
sever
cellular
pathway
find
highlight
anoth
level
concern
safe
clinic
use
sirna
alnylam
pharmaceut
cambridg
massachusett
wellestablish
sirnatherapeut
compani
whose
lead
candid
sirna
phase
ii
clinic
trial
sirna
target
respiratori
syncyti
viru
affect
almost
peopl
everi
year
unit
state
alon
silenc
viru
nucleocapsid
n
gene
gene
essenti
viral
replic
first
antivir
sirna
enter
clinic
trial
trial
soon
expand
paediatr
patient
thu
far
shown
effect
well
toler
recent
alnylam
pharmaceut
form
exclus
allianc
kyowa
hakko
kogyo
develop
commerci
japan
asian
countri
also
develop
alnylam
pharmaceut
sirna
direct
gene
implic
hypercholesterolaemia
huntington
diseas
joint
ventur
medtron
minneapoli
minnesota
hepat
c
joint
ventur
isi
pharmaceut
carlsbad
california
progress
multifoc
leukoencephalopathi
joint
ventur
biogen
idec
cambridg
massachusett
pandem
flu
joint
ventur
swiss
compani
novarti
intern
pachyonychia
congenita
consortium
ipcc
collabor
transderm
santa
cruz
california
develop
sirna
allow
correct
product
keratin
treatment
rare
skin
disord
call
pachyonychia
congenita
citi
hope
nation
medic
center
duart
california
collabor
benitec
melbourn
australia
start
phase
trial
treatment
aid
lymphoma
trial
use
pol
iii
promoterexpress
shrna
target
hiv
tat
rev
share
exon
shrna
incorpor
hivbas
lentivir
vector
turn
use
insert
shrna
gene
along
two
rnabas
antihiv
gene
blood
stem
cell
genemodifi
stem
cell
infus
hivposit
patient
trial
use
autolog
bone
marrow
transplant
treat
aidsrel
lymphoma
four
patient
treat
trial
indic
partnership
becom
quit
accept
field
sirna
biotechnolog
consortia
consider
increas
capit
avail
effort
shorten
time
involv
commerci
sirnabas
drug
compani
regulu
therapeut
carlsbad
california
chosen
focu
mirna
therapeut
target
santari
pharma
denmark
recent
start
first
phase
trial
target
human
mirna
trial
target
downregul
lock
nucleic
acid
lna
antimirna
lna
backbon
modif
enhanc
hybrid
oligonucleotid
target
protect
nucleas
degrad
approach
intend
treat
hepat
c
viru
infect
facilit
replic
viru
liver
downregul
also
potenti
use
treatment
hypercholesterolaemia
target
mirna
express
heart
regul
cardiac
hypertrophi
fibrosi
may
advantag
medic
field
consider
experi
deliv
drug
directli
organ
gain
loss
mirna
function
link
onset
progress
variou
diseas
protein
function
regul
either
directli
indirectli
mirna
alter
mirna
express
profound
effect
gene
regul
instanc
diseas
result
alter
mirna
express
conceiv
normal
level
could
achiev
either
target
specif
mirna
express
high
deliv
mirna
mimic
express
low
howev
specif
efficaci
deliveri
system
would
need
improv
goal
accomplish
moreov
correct
modul
target
mirna
express
easi
task
clear
whether
one
mirna
specif
target
without
affect
mirna
famili
regulatori
complex
mirna
also
taken
consider
either
ablat
restor
mirna
function
consid
therapeut
set
singl
mirna
regul
level
hundr
protein
rais
cautionari
flag
consequ
downregul
ectop
express
even
singl
mirna
speci
applic
sirna
therapeut
rais
number
concern
safeti
initi
excit
number
report
underscor
potenti
drawback
promis
technolog
first
warn
came
studi
record
death
mice
pol
iii
promoterdriven
express
shrna
liver
exact
mechan
lead
mortal
still
investig
seem
due
least
part
satur
transport
factor
exportin
ferri
mirna
nucleu
cytoplasm
indic
factor
involv
rnai
process
also
satur
highlevel
express
exogen
sirna
sequest
cognat
cellular
mirna
cellular
mirna
potenti
modul
express
sever
hundr
gene
minor
alter
mirna
pathway
major
consequ
one
strategi
mitig
problem
use
lowest
possibl
concentr
sirna
provid
therapeut
efficaci
design
exogen
sirna
dicer
substrat
increas
length
rna
enter
rnai
pathway
upstream
risc
step
dicer
cleavag
facilit
pass
sirna
select
guid
strand
often
result
enhanc
rnai
lower
concentr
achiev
exogen
deliveri
cognat
sirna
although
small
amount
sirna
expect
satur
rnai
machineri
compet
mirna
select
incorpor
risc
longterm
consequ
competit
poorli
understood
use
microarray
becom
increasingli
obviou
introduc
foreign
sirna
cell
alter
express
nontarget
gene
well
target
gene
six
seven
nucleotid
complementari
seed
region
could
result
specif
offtarget
effect
mirnalik
mechan
microarray
reflect
mrna
level
take
account
gene
affect
translat
level
present
clear
extens
problem
offtarget
effect
realli
given
applic
synthet
sirna
result
transient
inhibit
gene
express
specif
offtarget
may
major
concern
mani
clinic
applic
nevertheless
appropri
toxic
test
take
account
potenti
particular
sirna
target
utr
nontarget
gene
strategi
use
sirna
design
minim
problem
offtarget
instanc
shown
modif
dna
substitut
sirna
duplex
significantli
reduc
offtarget
effect
would
also
valuabl
improv
antisensestrand
select
take
account
thermodynam
stabil
see
superior
design
small
molecul
block
phosphoryl
sens
strand
rnai
wide
conserv
mechan
may
origin
evolv
combat
viral
infect
perhap
surpris
case
sirna
act
agonist
tolllik
receptor
specif
sequenc
motif
uridinerich
region
guano
sineand
uridinerich
region
induc
cellular
immun
respons
abil
sirna
stimul
cellular
immun
respons
base
specif
sequenc
also
structur
type
deliveri
system
use
cell
type
although
immunostimulatori
potenti
sirna
could
advantag
certain
circumst
usual
unwant
outcom
abovement
find
respons
nonsequencespecif
modul
vegf
vegf
receptor
well
separ
report
show
macrophag
migrat
inhibitori
factor
mif
target
sirna
murin
model
nonspecif
control
sirna
increas
prolifer
breast
cancer
cell
activ
dsrnaactiv
protein
kinas
pkr
rais
seriou
concern
interpret
result
vivo
sirna
applic
although
yet
reach
univers
solut
avoid
offtarget
effect
forese
problem
overcom
use
appropri
backbon
modif
well
deliveri
system
mask
rna
receptor
innat
immun
system
despit
techniqu
youth
list
diseas
rnai
test
therapeut
agent
extens
includ
parkinson
diseas
lou
gehrig
diseas
hiv
infect
wet
agerel
macular
degener
type
diabet
obes
hypercholesterolaemia
rheumatoid
arthriti
respiratori
diseas
cancer
alreadi
multimillion
dollar
busi
project
reach
us
billion
intellectu
properti
right
becom
increasingli
import
concern
come
year
howev
although
much
accomplish
obstacl
remain
hamper
race
clinic
ultim
goal
achiev
rnaibas
therapi
lifethreaten
debilit
diseas
attain
without
improv
safeti
effect
reliabl
rnaitrigg
deliveri
system
use
target
deliveri
strategi
permit
system
deliveri
big
step
toward
fulfil
difficult
task
develop
new
noninvas
imag
method
monitor
vivo
deliveri
sirna
label
nearinfrar
dye
aid
studi
tissu
uptak
biodistribut
although
rnai
yet
accept
therapeut
modal
enorm
interest
phenomenon
ensur
soon
wit
fast
advanc
new
applic
rnaibas
therapi
given
way
rnai
transform
basic
research
unpreced
speed
reach
clinic
come
year
promis
excit
figur
mechan
cellular
gene
silenc
primari
microrna
primirna
plant
anim
process
drosha
partner
precursor
mirna
premirna
transport
cytoplasm
exportin
cytoplasm
bound
dicercontain
prerisc
process
yield
guid
sequenc
load
holorisc
contain
compon
requir
gene
silenc
catalyt
core
risc
present
shown
schemat
drawn
holorisc
guid
sequenc
bind
correspond
target
sequenc
utr
cellular
mrna
mirna
guid
sequenc
fulli
complementari
target
site
left
pathway
trigger
sitespecif
cleavag
degrad
mrna
catalyt
domain
basepair
incomplet
right
pathway
includ
pair
seed
region
nucleotid
mirna
target
translat
inhibit
occur
accompani
nonsequencespecif
degrad
mrna
p
bodi
b
similarli
mirna
artifici
transcrib
shrna
case
plasmid
transport
cytoplasm
dsrna
cytoplasm
recogn
process
dicer
sirna
fragment
load
risc
sirna
target
complementari
sequenc
cellular
mrna
trigger
degrad
cleavag
c
sirna
present
nucleu
complementari
promot
region
trigger
chromatin
remodel
histon
modif
result
transcript
gene
silenc
mammalian
cell
detail
mechan
still
investig
known
includ
argonautefamili
protein
accessori
protein
figur
vivo
deliveri
strategi
therapeut
sirna
cholesterol
group
link
modifi
sirna
enhanc
stabil
system
deliveri
common
sirna
modif
substitut
blue
circl
combin
phosphorothio
linkag
b
polyc
nanoparticl
direct
deliveri
sirna
specif
cell
use
surfac
ligand
transferrin
bind
receptor
target
cell
c
snalp
encapsul
modifi
sirna
cation
neutral
lipid
bilay
coat
diffus
peglipid
conjug
snalp
allow
sirna
taken
cell
releas
endosom
mask
endosomolyt
agent
mea
dynam
polyconjug
dpc
similar
snalp
smaller
contain
ligand
allow
target
cell
deliveri
releas
sirna
endosom
also
improv
inclus
phlabil
bond
meadpc
particl
e
tag
specif
antibodi
protamin
posit
charg
allow
deliveri
sirna
specif
cell
type
via
receptormedi
uptak
f
chemic
link
cotranscrib
sirna
rna
aptam
allow
target
deliveri
sirna
cell
express
appropri
receptor
